Cell Source Shares Promising Interim Results From Groundbreaking Veto Cell Clinical Trial
Cell Source (OTCQB:CLCS) has announced promising interim results from its Phase 1/2 First-in-Human clinical trial of Veto Cell technology at MD Anderson Cancer Center. The trial, involving 15 patients with hematologic diseases, demonstrated successful engraftment without severe graft-versus-host disease (GvHD) using T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning. Key findings include consistent engraftment at 42 days post-transplant, no Veto Cell-related toxicity, and an enhanced protocol using mild conditioning with Rituximab. The technology aims to make transformative treatments more accessible for conditions ranging from leukemia to sickle cell disease.
Cell Source (OTCQB:CLCS) ha annunciato risultati intermedi promettenti dal suo studio clinico di Fase 1/2 First-in-Human sulla tecnologia Veto Cell presso il MD Anderson Cancer Center. Lo studio, che coinvolge 15 pazienti con malattie ematologiche, ha dimostrato un'infusione di cellule staminali compatibili con il donatore senza grave malattia del trapianto contro l'ospite (GvHD), utilizzando trapianti di cellule staminali ematopoietiche haploidentiche e depletate di cellule T sotto condizionamento a bassa intensità. I risultati chiave includono un'infusione costante a 42 giorni dopo il trapianto, nessuna tossicità correlata alle cellule Veto e un protocollo migliorato che utilizza un condizionamento lieve con Rituximab. La tecnologia mira a rendere i trattamenti trasformativi più accessibili per condizioni che vanno dalla leucemia alla malattia delle cellule falciformi.
Cell Source (OTCQB:CLCS) ha anunciado resultados intermedios prometedores de su ensayo clínico de Fase 1/2 First-in-Human sobre la tecnología Veto Cell en el MD Anderson Cancer Center. El ensayo, que involucra a 15 pacientes con enfermedades hematológicas, demostró un injerto exitoso sin enfermedad injerto contra huésped (GvHD) grave utilizando trasplantes de células madre haploidénticas y con depleción de células T bajo un condicionamiento de intensidad reducida. Los hallazgos clave incluyen un injerto constante a los 42 días después del trasplante, sin toxicidad relacionada con Veto Cell, y un protocolo mejorado que utiliza un acondicionamiento leve con Rituximab. La tecnología tiene como objetivo hacer que los tratamientos transformadores sean más accesibles para condiciones que van desde la leucemia hasta la enfermedad de células falciformes.
Cell Source (OTCQB:CLCS)는 MD Anderson Cancer Center에서 Veto Cell 기술에 대한 1/2 단계 첫 번째 인간 임상 시험의 중간 결과를 발표했습니다. 이 시험에는 혈액 질환이 있는 15명의 환자가 참여했으며, T 세포가 고갈된 반합자성을 가진 줄기세포 이식을 통해 GvHD(이식편 대 숙주 병)가 심각하지 않게 성공적인 이식을 입증했습니다. 주요 발견에는 이식 후 42일째에 일관된 이식, Veto Cell 관련 독성이 없음, 및 Rituximab을 사용한 경미한 조건화가 있는 향상된 프로토콜이 포함됩니다. 이 기술은 백혈병에서 겸상적혈구병까지 다양한 질환에 대한 혁신적인 치료를 보다 쉽게 접근할 수 있도록 하는 것을 목표로 하고 있습니다.
Cell Source (OTCQB:CLCS) a annoncé des résultats intermédiaires prometteurs de son essai clinique de Phase 1/2 First-in-Human sur la technologie Veto Cell au MD Anderson Cancer Center. L'essai, qui implique 15 patients atteints de maladies hématologiques, a démontré un greffement réussi sans maladie du greffon contre l'hôte (GvHD) sévère en utilisant des greffes de cellules souches haplo-identiques et déplétées en cellules T sous conditionnement à faible intensité. Les principaux résultats incluent un greffement constant à 42 jours après la transplantation, aucune toxicité liée aux cellules Veto et un protocole amélioré utilisant un conditionnement léger avec le Rituximab. La technologie vise à rendre les traitements transformateurs plus accessibles pour des conditions allant de la leucémie à la maladie des cellules falciformes.
Cell Source (OTCQB:CLCS) hat vielversprechende Zwischenresultate aus seiner klinischen Studie der Phase 1/2 First-in-Human zur Veto Cell-Technologie am MD Anderson Cancer Center bekannt gegeben. Die Studie, an der 15 Patienten mit hämatologischen Erkrankungen teilnahmen, zeigte eine erfolgreiche Verpflanzung ohne schwere Transplantat-gegen-Wirt-Krankheit (GvHD) unter Verwendung von T-Zell-depletierten haploidentischen Stammzelltransplantationen unter reduziert intensiver Konditionierung. Wesentliche Ergebnisse umfassen eine konsistente Verpflanzung 42 Tage nach der Transplantation, keine Veto Cell-bezogene Toxizität und ein verbessertes Protokoll, das eine milde Konditionierung mit Rituximab verwendet. Die Technologie zielt darauf ab, transformative Behandlungen für Erkrankungen von Leukämie bis zur Sichelzellenkrankheit zugänglicher zu machen.
- Successful interim results showing both safety and efficacy in Phase 1/2 trial
- No patients experienced adverse effects from Veto Cells
- Technology addresses $100+ billion total addressable market
- Potential application expansion to organ transplant procedures
- Early-stage trial results (Phase 1/2) still require further validation
- Trading on OTCQB market indicates lower tier exchange listing
First-of-Its-Kind Success in Mismatched Donor Stem Cell Transplantation: Engraftment Under Mild Immune Suppression with Minimal Graft-versus-Host Disease
NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source", or the "Company"), a pioneer in Veto Cell-based immunotherapy, today shared positive interim results from its Phase 1/2 First-in-Human clinical trial conducted at The University of Texas MD Anderson Cancer Center. The trial has treated 15 patients using Cell Source's proprietary Veto Cell technology in stem cell transplants for malignant and non-malignant hematologic diseases. These early results indicate both safety and efficacy, marking a promising advance in stem cell transplant outcomes.
"Our Veto Cell platform aims to overcome two significant challenges in stem cell therapy: preventing severe graft-versus-host disease (GvHD) while reducing treatment toxicity. With this safer, more patient-friendly approach, we are closer to making transformative treatments accessible for individuals with a variety of hematologic conditions, ranging from leukemia and lymphoma to sickle cell disease," said Dr. Dennis Brown, Chairman of Cell Source, Inc.
Breakthrough Results for Safer and Effective Transplants
Previously presented at the American Society for Hematology (ASH) Annual Meeting, the interim study results highlight:
Consistent engraftment without severe GvHD: Achieved at 42 days post- transplant with T-cell-depleted, haploidentical stem cell transplants under reduced intensity conditioning (RIC).
No toxicity linked to Veto Cells: No patients experienced adverse effects directly associated with Veto Cells.
Enhanced protocol: A mild conditioning regimen, combined with Rituximab to prevent antibody-related complications, makes transplants safer and suitable for a broader range of patients.
These findings underscore the potential of Veto Cells to increase access to life-saving allogeneic transplants for cancer patients and individuals with non-malignant blood disorders, supporting the strategic advancement of Cell Source's technology.
Comparable Successes Demonstrate Market Potential
The cell therapy and immunotherapy market has seen robust investor interest, with several start-up companies achieving multibillion-dollar valuations after clinical success. For example, Kite Pharma and Juno Therapeutics were acquired for
With Cell Source's Veto Cell platform showing early promise in achieving safer and thus more effective stem cell transplants without severe GvHD, the Company is strategically positioned to capitalize on this expanding market. The total addressable market (TAM) for hematological therapeutics, including both cancer and nonmalignant diseases, is estimated to be in excess of
Pathway to Market and Competitive Edge
Cell Source's Veto Cell technology offers a unique advantage by combining reduced immune suppression with avoidance to GvHD, making it an attractive alternative to current stem cell transplant methods. The Company's Veto Cell platform is also being developed for organ transplant applications, potentially allowing for partially mismatched donors as well as reducing or possibly even eliminating reliance on lifelong immunosuppression post-transplant.
Expanding the Investor Base and Future Updates
As Cell Source advances its clinical program, the Company invites investors to explore the potential of its Veto Cell technology through our Investor Resource Center, where shareholders and prospective investors can access comprehensive information on financials, SEC filings, and the latest corporate updates. Cell Source anticipates additional milestones in 2024 and looks forward to providing further updates.
About Cell Source, Inc.
Cell Source, Inc. (OTCQB:CLCS) is the worldwide, exclusive innovator of Veto Cell-based cellular therapy and immunotherapy platform technologies designed to provide safer and more accessible stem cell (e.g. bone marrow)transplantation and improve the treatment of blood cancers such as leukemia, lymphoma and multiple myeloma. The company licenses the technology from The Weizmann Institute of Science in Israel and sponsors both research and clinical development at The University of Texas MD Anderson Cancer Center. In addition, its Veto Cell platform is being developed to reverse sickle cell disease and other non-malignant genetic blood disorders and to durably treat autoimmune diseases such as type 1 diabetes. The Company is also developing a Veto Cell CAR-T platform which could potentially enable CAR-T therapy to be used in donor-derived (allogeneic) settings with increased safety, efficacy, and persistence. Cell Source's Veto Cell technologies are also being developed to facilitate safer, donor mismatched organ transplants (e.g., kidney and liver) and also avoid the current need for life-long daily immune system suppression.
The Company is focused on transitioning this allogeneic Veto Cell platform into additional clinical trials in order to develop safe and curative cell therapy treatments (such as stem cell transplants) from mismatched donors as well as safe, durable, and efficacious "off- the-shelf" immunotherapy and immuno-oncology products.
For more information, visit cell-source.com.
Investor Contact
Brendan Rempel
brendan@alternativeadvisory.com
Cautionary Note on Forward-Looking Statements
This press release contains forward- looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on June 6, 2024. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact Information
Itamar Shimrat
CEO
info@cell-source.com
6464167896
SOURCE: Cell Source, Inc.
View the original press release on accesswire.com
FAQ
What are the key findings from Cell Source's (CLCS) Phase 1/2 clinical trial?
How many patients were treated in Cell Source's (CLCS) Veto Cell clinical trial?
What is the market potential for Cell Source's (CLCS) Veto Cell technology?
What conditions can Cell Source's (CLCS) Veto Cell technology potentially treat?
